AI assistant
Sending…
UroGen Pharma Ltd. — Director's Dealing 2023
Jan 23, 2023
32312_dirs_2023-01-23_8012333c-c55e-486d-8079-aa1d857fac8c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2023-01-20
Reporting Person: Schoenberg Mark (Chief Medical Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-01-20 | Ordinary Shares | M | 122677 | $5 | Acquired | 146627 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-01-20 | Employee Stock Option (right to buy) | $5 | M | 122677 | Disposed | 2023-01-20 | Ordinary Shares (122677) | Direct |
More from UroGen Pharma Ltd.
Annual Report
2026
May 27
Interim / Quarterly Report
2026
May 6
Regulatory Filings
2026
May 6
Proxy Solicitation & Information Statement
2026
Apr 30
Annual Report
2026
Mar 2
Regulatory Filings
2026
Mar 2
Regulatory Filings
2026
Mar 2
Director's Dealing
2026
Feb 27
Director's Dealing
2026
Feb 19
Director's Dealing
2026
Feb 11